4basebio (LON:4BB) Announces Quarterly Earnings Results

4basebio (LON:4BB) posted its quarterly earnings results on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

4basebio Stock Performance

Shares of 4BB opened at GBX 559.80 on Tuesday. The stock’s 50-day simple moving average is GBX 511.05 and its 200 day simple moving average is GBX 510.01. 4basebio has a 52-week low of GBX 420 and a 52-week high of GBX 820. The stock has a market capitalization of £86.69 million, a price-to-earnings ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reduced their target price on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of GBX 1,400.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.